Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

The primary purpose of this study is to determine whether the investigational drug XmAb541 is safe and well tolerated, and to determine an optimal and safe dose(s) for further study. The study will also evaluate the effect of XmAb541 on tumor outcomes.

Trial Details

NCT ID
NCT06276491
Phase
PHASE1
Sponsor
Xencor, Inc.
Status
RECRUITING
Cancer Type
Uterine Cancer
Interventions
  • XmAb541
Locations (sample)
  • Duarte, California, United States|34.13945,-117.97729
  • Palo Alto, California, United States|37.44188,-122.14302
  • San Francisco, California, United States|37.77493,-122.41942
  • Tampa, Florida, United States|27.94752,-82.45843
  • Atlanta, Georgia, United States|33.749,-84.38798

Key Eligibility Criteria

  • Age ≥ 18 years. For US only: subjects with GCTs, age ≥15 years
  • CLDN6+ tumor
  • Histological or cytological documentation of locally advanced, recurrent, or metastatic ovarian, fallopian tube, or peritoneal cancer, adenocarcino…
  • Adequate Eastern Cooperative Oncology Group performance status

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Uterine Cancer Trials on Trialify →